GlassScriptPhysician profile
Adriana Hohl
NPI 1982602462
$1,530.99
in general payments reported to CMS, 2019-2025
23 companies · $528 in 2025
The $528 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $134 · 2022: $18.08 · 2023: $174 · 2024: $230 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $124.50 | 2019-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Glaxosmithkline, LLC. | $113.10 | 2019-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $101.33 | 2019-2025 | Veozah |
| Medtronic, INC. | $98.46 | 2023-2025 | Closurefast, Minimed 780g |
| Abbvie INC. | $82.99 | 2019-2025 | |
| Valeritas, INC. | $81.59 | 2019 | |
| Seqirus USA INC | $77.61 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Phathom Pharmaceuticals, INC. | $66.93 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $58.23 | 2019-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $56.59 | 2025 | |
| Dexcom, INC. | $55.95 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $54.87 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $48.77 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $33.72 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $31.63 | 2019-2023 | |
| Globus Medical, INC. | $28.24 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $27.59 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.12 | 2019 | |
| Corcept Therapeutics | $20.98 | 2020 | |
| Abbott Laboratories | $20.53 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Hohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.